Antipsychotic Labels Will Highlight Need For Proper Diagnoses Of Bipolar Kids
Executive Summary
The Highlights section of labeling for three atypical antipsychotic drugs with sNDAs for pediatric indications pending at FDA would emphasize the importance of correctly diagnosing bipolar disorder, Office of Drug Evaluation I Director Bob Temple said at a recent advisory committee meeting